MDVX - MedoveX Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
0.5075
+0.0275 (+5.73%)
At close: 1:15PM EDT
Stock chart is not supported by your current browser
Previous Close0.4800
Open0.5075
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.5075 - 0.5075
52 Week Range0.2110 - 0.6500
Volume1,000
Avg. Volume49,090
Market Cap45.789M
Beta (3Y Monthly)-0.58
PE Ratio (TTM)N/A
EPS (TTM)-0.2340
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.75
Trade prices are not sourced from all markets
  • GlobeNewswire13 days ago

    Medovex Corporation Closes Financing for a Total $7.2M Under Existing Securities Purchase Agreement

    Medovex Corporation (MDVX) (“Medovex” or the “Company”) today announced that on April 1, 2019, the Company entered into a securities purchase agreement with five purchasers pursuant to which the five purchasers invested in the Company an aggregate amount of $575,000. Previously on March 11, 2019, the Company entered into a securities purchase agreement with eight purchasers pursuant to which the purchasers invested in the Company an aggregate amount of $1,250,000.

  • GlobeNewswirelast month

    Medovex Corporation Receives an Additional $1.25 Million Under Existing Securities Purchase Agreement

    Medovex Corporation (MDVX) (“Medovex” or the “Company”) today announced that on March 11, 2019, the Company entered into a securities purchase agreement with eight purchasers pursuant to which the purchasers invested in the Company an aggregate amount of $1,250,000. The Company last announced on January 18, 2019, it had entered into a securities purchase agreement with six purchasers pursuant to which the purchasers invested in the Company an aggregate amount of $2,900,000.

  • GlobeNewswire2 months ago

    Medovex Corporation Announces Name Change and Full Rebranding to Blue Zone Health

    Medovex Corporation (MDVX) (“Medovex” or the “Company”) today announced it is now Blue Zone Health. The announcement signals the company's broader commitment to bringing new health care solutions to patients domestically and internationally with a focus on improving quality of life, especially for those with chronic diseases. Blue Zone Health adopts its name from the “Blue Zones,” research spearheaded by Dan Buettner, showing the key to longevity lies in a holistic, daily approach to wellness.

  • GlobeNewswire3 months ago

    Medovex Corporation Receives an Additional $2.9 Million Under Existing Securities Purchase Agreement

    Medovex Corporation (MDVX) (“Medovex” or the “Company”) today announced that on January 18, 2019, the Company entered into a securities purchase agreement with six purchasers pursuant to which the purchasers invested in the Company an aggregate amount of $2,900,000. Medovex previously announced that on January 8, 2019, the Company entered into a securities purchase agreement with four purchasers pursuant to which the purchasers invested in the Company an aggregate amount of $2,000,000, with $1,800,000 in cash and $200,000 by cancellation of debt.

  • GlobeNewswire3 months ago

    Medovex Corporation Enters into Securities Purchase Agreement

    Medovex Corporation (MDVX) (“Medovex” or the “Company”) today announced that on January 8, 2019, the Company entered into a securities purchase agreement with four purchasers pursuant to which the purchasers invested in the Company an aggregate amount of $2,000,000, with $1,800,000 in cash and $200,000 by cancellation of debt. The agreement includes the customary representations and warranties from the Company and purchasers.

  • GlobeNewswire3 months ago

    Medovex Corporation Announces New Board Appointments

    Medovex Corporation (MDVX) (“Medovex” or the “Company”) today named Michael Yurkowsky, founder of YP Holdings, and Raymond Monteleone, formerly of Arthur Young (now EY), to its board of directors, effective immediately.

  • GlobeNewswire3 months ago

    Medovex Corporation Closes Acquisition of Pulmonary Biomedical Services and Patient Delivery Platform of Regenerative Medicine Solutions, LLC

    Medovex Corporation (MDVX) (“Medovex” or the “Company”) today announced that it has closed the acquisition of substantially all of the assets of Regenerative Medicine Solutions, LLC (“RMS”). RMS is a Tampa, Florida-based pulmonary biomedical services and patient delivery platform that manages and operates Lung Health Institute, a leader in regenerative medicine specializing in cellular therapies to treat chronic obstructive pulmonary disease (COPD) and other chronic lung diseases.